Revolutionary Fingerstick Test for Hepatitis B Shows Promise in Australia

A recent Australian trial has introduced a fingerstick test for hepatitis B DNA that matches the accuracy of traditional lab tests. This innovative method can deliver results in under an hour, making it a significant advancement for healthcare in remote areas. With hepatitis B affecting millions globally and treatment access being limited, this new testing approach could revolutionize how patients receive care. The study highlights the potential for this test to support global health initiatives aimed at eliminating hepatitis B as a public health threat by 2030. Discover how this breakthrough could change the landscape of hepatitis B testing and treatment.

By Narendra Chaudhary Feb 5, 2026, 17:01 IST

Innovative Testing Method for Hepatitis B

New Delhi, Feb 5: A groundbreaking trial conducted in Australia has revealed that a fingerstick test for hepatitis B DNA is just as reliable as conventional laboratory tests. This advancement could significantly enhance access to testing in remote and under-resourced areas.

According to a study published in the Journal of Clinical Microbiology, this point-of-care test can yield results in under an hour and can be administered in decentralized healthcare facilities, as reported by a news agency.

The fingerstick method addresses the delays often associated with laboratory testing, as noted by the Kirby Institute at the University of New South Wales.

Professor Gail Matthews, who spearheaded the research, stated, "Our trial results indicate that the fingerstick point-of-care test is highly precise, closely aligning with the accuracy of traditional testing methods."

This innovation has the potential to broaden access to testing and treatment worldwide, particularly in regions where testing facilities are scarce, Matthews added.

Globally, hepatitis B, a viral infection impacting the liver, affects around 254 million individuals and results in over 1 million fatalities each year, according to international health statistics.

Despite being preventable through vaccination, only about 8% of those with chronic hepatitis B receive adequate treatment, as per the World Health Organization (WHO).

Currently, testing for hepatitis B DNA necessitates a venous blood sample, which must be processed in centralized labs. This often requires patients to travel long distances and wait days or even weeks for their results, which can delay necessary treatment.

In contrast, the new point-of-care test can be performed in smaller health clinics using a fingerstick blood sample, allowing a wider range of healthcare providers to administer it and providing results within 60 minutes.

This method is a viable alternative for testing various infectious diseases, including hepatitis C, but its effectiveness for hepatitis B DNA using fingerstick samples had not been previously established.

The researchers believe that this new testing approach could aid global initiatives aimed at achieving the WHO's goal of eliminating hepatitis B as a public health concern by 2030.